Synergistic Inhibition of Breast Carcinoma Cell Proliferation by Quercetin and Sulforaphane via Activation of the ERK/MAPK Pathway
Cell Biochemistry and Biophysics · 2025
DOI: 10.1007/s12013-024-01662-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Biophysics, 2025. Verfasst von Ranmei Wei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Diseases, Hospital of Traditional Chinese Medicine of Qiqihar, Qiqihar, Heilongjiang, China. Hauptthemen laut MEDLINE: Isothiocyanates, Quercetin, Breast Neoplasms, MAP Kinase Signaling System. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
In the contemporary era of drug discovery, herbal treatments have demonstrated an unparalleled ability to produce anticancer drugs. An important part of the therapy of cancer is the use of plants and their by-products via analogues, which alter the tumor microenvironment and several signaling pathways. The objective of the current investigation was to conclude the rate at which the herbal medications quercetin (QT) and sulforaphane (SFN) repressed the growth of breast carcinoma cells in MDA-MB-231 by preventing the ERK/MAPK signaling systems. The cells were assessed for several studies after being subjected to different concentrations (0-70 µM) of QT and SFN (QT + SFN) for duration of 24 h. We investigated the combination that QT + SFN generated cytotoxicity using the MTT assay. The DCFH-DA staining technique was utilized to assess ROS. The protein spectra of survival of cells, cell cycle progression, and apoptosis were evaluated employing flow cytometry and western blotting. The consequences illustrated that the relative cytotoxicity of QT and SFN was roughly 28.74 μM and 39.87 μM for MDA-MB-231 cells, respectively. Following the 24-h incubation period, MDA-MB-231 cells exhibit considerable cytotoxicity when QT and SFN are combined, with IC50 values of 19.48 μM. Moreover, MCF-7 and MDA-MB-231 cells treated with QT and SFN concurrently showed substantial production of ROS and increased apoptotic signals. Consequently, because QT + SFN inhibit the production of ERK/MAPK/JNK/p38-based control of proliferation and cell cycle-regulating proteins, it has been considered a chemotherapeutic medication. To determine the extent to which the co-treatment induces apoptosis, more in vivo study will be required before they can be used commercially.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Diseases, Hospital of Traditional Chinese Medicine of Qiqihar, Qiqihar, Heilongjiang, China.
- Department of the 0perating Room,Huaian Hospital of Huaian City, Huaian Cancer Hospital, Huaian, Jiangsu, China.
- Outpatient Department, General hospital of the western theater command of Chinese people's liberation army, Chengdu, Sichuan, China.
- Pharmacy Administration Office, The Third Hospital of Nanchang City, Jiangxi Province, Nanchang, Jiangxi, China. panlili@ncmc.edu.cn.
Zitieren
APA
Wei, R., Pan, X., Cai, D., & Pan, L. (2025). Synergistic Inhibition of Breast Carcinoma Cell Proliferation by Quercetin and Sulforaphane via Activation of the ERK/MAPK Pathway. Cell Biochemistry and Biophysics. https://doi.org/10.1007/s12013-024-01662-6
Vancouver
Wei R, Pan X, Cai D, Pan L. Synergistic Inhibition of Breast Carcinoma Cell Proliferation by Quercetin and Sulforaphane via Activation of the ERK/MAPK Pathway. Cell Biochemistry and Biophysics. 2025. doi:10.1007/s12013-024-01662-6
BibTeX
@article{Wei2025,
author = {Wei, Ranmei and Pan, Xingchen and Cai, Danni and Pan, Lili},
title = {Synergistic Inhibition of Breast Carcinoma Cell Proliferation by Quercetin and Sulforaphane via Activation of the ERK/MAPK Pathway},
journal = {Cell Biochemistry and Biophysics},
year = {2025},
doi = {10.1007/s12013-024-01662-6}
}
EUVIMED